gsk

GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences

GSK plc (LSE/NYSE: GSK) today announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences (Chimagen), a privately held ...
gsk

GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data

GSK plc (LSE/NYSE: GSK) presented positive phase II data for its mRNA seasonal influenza (flu) vaccine candidate at the OPTIONS XIII Conference for the Control of Influenza. GSK’s vaccine candidate ...
gsk

Media library

GSK images and video for use by journalists.
gsk

GSK enters exclusive license agreement with Hansoh for HS-20089

GSK plc (LSE/NYSE: GSK) and Hansoh Pharma (HKEX: 03692), a Chinese biopharmaceutical company committed to discovering and developing life-changing medicines to help patients conquer serious diseases ...
gsk

GSK delivers strong Q1 performance and start to 2026

Luke Miels, Chief Executive Officer, GSK: “GSK has made a strong start to 2026, with good performance from our key growth drivers. Alongside operational delivery, we are focused on execution and ...
gsk

GSK announces commencement of tender offer to acquire Nuvalent, Inc.

GSK plc (LSE/NYSE: GSK) today announced that Harmony Row Acquisition Co. (“Purchaser”), a direct wholly-owned subsidiary of ‎GlaxoSmithKline LLC (“GSK LLC”), which is an ‎indirect wholly-owned ...
gsk

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease 1 Next-generation design aims to address key efficacy ...
gsk

GSK completes acquisition of Nuvalent, Inc.

GSK plc (LSE/NYSE: GSK) today announced completion of its acquisition of Nuvalent, Inc. 1, a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology ...
gsk

GSK enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans

Voluntary agreement delivers on all four of President Trump’s requests and reduces the cost of medicines for Americans Includes products used to treat the more than 40 million patients in the U.S. who ...
gsk

GSK’s investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) designations for MASH

Phase II data show once-monthly efimosfermin improved liver fibrosis (scarring), a key driver of disease progression in metabolic dysfunction-associated steatohepatitis (MASH) MASH is a leading cause ...
gsk

Price of world’s first malaria vaccine (RTS,S) for children in endemic countries to be reduced by more than half, to less than $5

Price reduction is commitment by Bharat Biotech, made possible through partnership with GSK and driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal ...
gsk

GSK enters agreement to acquire 35Pharma Inc.

Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases HS235 offers potential to treat pulmonary ...